Novel heterocycles

Abstract

The present invention relates to novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel hetereocycles of the general formula (I). Also included is a method of treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection in a mammal comprising administering an effective amount of a compound of formula (I) as described above.

Description

Claims

1. A compound of the general formula (I),

2. The heterocyclic compound of claim 1, selected from a group consisting of:

3. A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1, as an active ingredient along with a pharmaceutically acceptable carrier, diluent, excipient or solvate.

4. A pharmaceutical composition as claimed in claim 3, wherein the pharmaceutical composition is in a tablet, capsule, powder, syrup, solution, aerosol or suspension.

5. A pharmaceutical composition as claimed in claim 3, wherein the amount of the compound in the composition is less than 70% by weight.

6. A method of treatment of a pain disorder, inflammation, and immunological diseases in a mammal comprising administering an effective amount of, a compound according to claim 1, to the mammal in need thereof.

7. A method of treatment of rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection in a mammal comprising administering an effective amount of, a compound according to claim 1, to the mammal in need thereof.

8. A method of lowering plasma concentrations of anyone or a combination or all of TNF-α, IL-1β, and IL-6 comprising administering an effective amount of a compound according to claim 1, to the mammal in need thereof.

9. A method for inhibiting production of cytokines as selected from TNF-α, IL-1β, and IL-6, by the method comprising of administering the compound of the formula (I) as claimed in claim 1.

10. A method of treating immunological diseases, those mediated by cytokines such as TNF-α, IL-1β, and IL-6 comprising administering an effective amount of a compound according to claim 1, to the mammal in need thereof.